Inc. ("bluebird") today confirmed it has received an unsolicited non-binding written proposal (the "Ayrmid Proposal") from Ayrmid Ltd ("Ayrmid") to acquire bluebird for an upfront cash payment of ...

BlackBerry (NYSE: BB) and Unity Software (NYSE: U) were both once high-growth tech stocks that lost their momentum and ...

Just a few months after dumping its lead asset and cutting its workforce in half, Cargo Therapeutics is jettisoning even more ...

The biotech is exploring opportunities for a reverse merger or other business combinations. CFO and now interim CEO Anup ...

Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize ...

Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value - - CARGO had cash, cash equivalents ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

The traditional perimeter is no longer what protects our critical information and systems. In 2025, securing data is dependent on identity. With distributed multi-cloud, multi-IDP environments, the ...

Five months after giving up on its lead drug Betalutin for follicular lymphoma, Nordic Nanovector has charted a course forward via a merger with fellow Norwegian biotech APIM Therapeutics.

Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Nordic Nanovector pitched the APIM merger as a swift way to transition to a clinical-stage cancer-focused biotech with a pipeline headed by ATX-101, a peptide-targeting PCNA in trials for platinum ...

The construction industry continued to see either growth or stability in all its sectors in 2024. Anchored by a large thrust ...